Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
about
Optimal classifier selection and negative bias in error rate estimation: an empirical study on high-dimensional predictionInterpretation of microarray data in cancerMolecular signatures from omics data: from chaos to consensusHow do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experimentTargeted therapies with companion diagnostics in the management of breast cancer: current perspectivesBreast cancer intrinsic subtype classification, clinical use and future trendsIdentifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomesBiological markers of invasive breast cancerIntegrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potentialBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesMultigene assays and molecular markers in breast cancer: systematic review of health economic analysesPrognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?Imaging tumour heterogeneity of the consequences of a PKCĪ±-substrate interaction in breast cancer patientsThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisGenomic profiling in luminal breast cancerUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Signatures of breast cancer metastasis at a glanceHormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal WomenUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineThe MINDACT trial: the first prospective clinical validation of a genomic toolRole of MTA2 in human cancerDiscovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancerIntegrative computational biology for cancer researchDerivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approachEvaluating microarray-based classifiers: an overviewBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy.Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.A pathway-based data integration framework for prediction of disease progressionStatistical aspects of omics data analysis using the random compound covariateA data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.Network Based Prediction Model for Genomics Data Analysis.Good practice guidelines for biomarker discovery from array data: a case study for breast cancer prognosis.Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.An experimental loop design for the detection of constitutional chromosomal aberrations by array CGH.Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.
P2860
Q24288960-FF471C33-1BC5-40FA-B3F1-7B9FE9338547Q24289307-4035B974-000C-4A7D-973C-9D5FDE092B45Q24289539-D05B2DF7-9A9B-4070-8727-D8147B791117Q24658523-626AD189-C933-4C50-B3C6-7928ADC067C8Q26768119-D12E3221-BF07-43B7-9AC3-03A9254442E5Q26773761-D36716D4-DD5D-4939-A223-AAF69B9C9C26Q26778675-38DF713F-4737-4516-A96E-0D0BB1A9306CQ26781177-D7B9B5DB-66DA-46D7-856E-6ED0DD3A935AQ26782613-BD12872A-E2E6-43BD-9113-31C4B4A10ED2Q26783705-DC646E3C-D244-4037-9424-3FEC6F262CD7Q26825362-E75F57CA-4A99-47EB-B519-15FE5B58EDECQ26830362-8D6335A7-E0F4-4FD4-9846-085E2978D713Q26858812-5CC5BA66-A7D1-478A-9E93-FA2B244E6BE3Q26861418-EB538306-E1D6-4D39-A268-3B43B76C505BQ26862681-05EE5E93-763F-4081-B954-303002DECEB4Q27020973-35D1C549-9C28-425C-8156-FCDA68D43220Q28068956-5766E6E7-5F20-4712-99E4-B2537F98CE92Q28071451-6F5A4330-399A-440E-A8B0-EBB571466C5BQ28077637-889FBD67-4DF2-4437-830B-DDEF636EDEF6Q28079118-1281390A-7695-40A8-B7D8-483BBAE48A71Q28242008-80CC5B9D-F57F-4F80-8D68-20D0F5D0ADEDQ28251565-13F48F37-76DE-482A-8F28-B0D7663EE379Q28743801-BD46DA8F-22EF-4259-BD97-88237795CD78Q28744621-B621381D-4901-4F3F-B66B-7ADE4DDB6A6CQ28748329-F100D88C-4E3B-4D79-AAA2-BFD1E7F68351Q28761774-D344C894-6B14-4EB8-8B75-029904F99FBCQ30245184-143E8E88-C0E1-4574-B169-ACB723A7C28BQ30423830-46A501B9-45EE-4D5A-A695-D29C67F63A7EQ30440216-3B3A676A-E412-48CA-B938-226AB747AB0FQ30485127-D44DA653-863F-4A6D-B9D9-39F8C3078C76Q30512428-A7BDD8B2-81EB-4162-8A25-CBF56F9438A5Q30574210-9C91580D-7837-4220-B4D9-B2FD7B6D2EA9Q30584008-005948B2-7D72-40CB-9F4D-5BDDACD146A4Q30587056-6A8D8E3C-6A10-4C8F-9860-8A6919178B22Q30717730-F70B5A51-4DBE-4545-9138-9AEC24E46C11Q30763493-2ACE783F-CF6B-419D-9099-222CDFC407F2Q30768230-EFD1425B-1612-419C-9551-96D1E3233F3CQ30854643-AC5B8246-5203-4990-9C07-01D2533A8CF8Q30898664-1BD8262F-82E2-48C1-934D-31CA5658F2D8Q31028108-7D4247F7-4B33-4164-97C4-96926301CA99
P2860
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2006 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ½Õ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
name
Validation and clinical utilit ...... h node-negative breast cancer.
@ast
Validation and clinical utilit ...... h node-negative breast cancer.
@en
Validation and clinical utilit ...... h node-negative breast cancer.
@nl
type
label
Validation and clinical utilit ...... h node-negative breast cancer.
@ast
Validation and clinical utilit ...... h node-negative breast cancer.
@en
Validation and clinical utilit ...... h node-negative breast cancer.
@nl
prefLabel
Validation and clinical utilit ...... h node-negative breast cancer.
@ast
Validation and clinical utilit ...... h node-negative breast cancer.
@en
Validation and clinical utilit ...... h node-negative breast cancer.
@nl
P2093
P2860
P50
P356
P1476
Validation and clinical utilit ...... h node-negative breast cancer.
@en
P2093
Annuska M Glas
Arno Floore
Christos Sotiriou
Emiel Rutgers
Fanny Piette
Jan Bogaerts
Jonas Bergh
Laura van't Veer
Mahasti Saghatchian d'Assignies
Martine J Piccart
P2860
P304
P356
10.1093/JNCI/DJJ329
P407
P577
2006-09-01T00:00:00Z